191 related articles for article (PubMed ID: 21226265)
1. [Anti-atherosclerotic and anti-inflammatory effects of statin on cardiovascular disease and their mechanisms].
Ishibashi T
Nihon Rinsho; 2011 Jan; 69(1):79-84. PubMed ID: 21226265
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
4. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
5. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
6. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Albert MA; Staggers J; Chew P; Ridker PM;
Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Patrick L; Uzick M
Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
Kitamoto S; Nakano K; Hirouchi Y; Kohjimoto Y; Kitajima S; Usui M; Inoue S; Egashira K
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1522-8. PubMed ID: 15178560
[TBL] [Abstract][Full Text] [Related]
13. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
15. Statins and cardioprotection--more than just lipid lowering?
Ludman A; Venugopal V; Yellon DM; Hausenloy DJ
Pharmacol Ther; 2009 Apr; 122(1):30-43. PubMed ID: 19318042
[TBL] [Abstract][Full Text] [Related]
16. [The pleiotropic effects of statins].
Wolfovitz E
Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?
Efthimiadis A
Angiology; 2008; 59(2 Suppl):62S-4S. PubMed ID: 18628276
[TBL] [Abstract][Full Text] [Related]
18. Plaque regression and improved clinical outcomes following statin treatment in atherosclerosis.
Girotra S; Murarka S; Migrino RQ
Panminerva Med; 2012 Jun; 54(2):71-81. PubMed ID: 22525562
[TBL] [Abstract][Full Text] [Related]
19. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Ray KK; Cannon CP; Ganz P
Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
[TBL] [Abstract][Full Text] [Related]
20. [Two decades of statin trials: clinical, intermediate and surrogate endpoints].
Fabbri G; Di Pasquale G; Greco C; Musuraca AC; Tavazzi L
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):18S-24S. PubMed ID: 21298857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
